Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus

Background Both HMG‐CoA reductase inhibitors and fibric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG‐CoA reductase inhibitor, and 400 mg bezafibrate, a fibric acid derivate, on serum lipids, lipoproteins and lipoprotein composition in 45 (22 men and 23 women) dyslipidemic, insulin‐treated Type 2 diabetes patients. Method The study used a double‐blind, cross‐over design. Results Pravastatin treatment was more effective in reducing total cholesterol, LDL‐cholesterol, LDL‐triglycerides, LDL‐ApoB and LDL/HDL‐cholesterol ratio (all p